NCT04424485

Brief Summary

Indocyanine green (ICG) is a water-soluble organic dye that is cleared totally through the hepatobiliary system. It has a half-life of 3-4 mins, which allows repeated applications. Near-infrared (NIR) fluorescence imaging with indocyanine green (ICG) imaging has been recently introduced, and has been suggested as a useful tool for the identification and preservation of the parathyroid glands (PGs) during total thyroidectomy (TT). ICG can also be used for sentinel lymph node (SLN) biopsy to predict the micrometastases in central lymph nodes (CLN) in thyroid carcinoma, and central lymph node dissection can reduce local recurrence.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2020

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

June 2, 2020

Completed
9 days until next milestone

First Posted

Study publicly available on registry

June 11, 2020

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2021

Completed
Last Updated

June 11, 2020

Status Verified

June 1, 2020

Enrollment Period

1 year

First QC Date

June 2, 2020

Last Update Submit

June 5, 2020

Conditions

Keywords

Near-infrared (NIR) fluorescenceTotal thyroidectomyParathyroid glandsIndocyanine green (ICG)Central lymph node dissection

Outcome Measures

Primary Outcomes (2)

  • Involvement of sentinel lymph node (presence/absence of tumor cell: positive or negative) by histopathological examinatiion

    Intrathyroidal injection of indocyanine green (ICG) dye to identify sentinel lymph node (SLN) for biopsy

    1 year

  • Identification of parathyroid glands (PGs) by NIR/ICG camera detected high-contrast

    İntravenous injection of ICG dye, to identify PGs under NIR (High-contrast fluorescence seen or not)

    1 year

Secondary Outcomes (1)

  • Central lymph node dissetion (CLND)

    1 year

Study Arms (2)

Thyroid carcinoma patients (biopsy-proven)-Total thyroidectomy

ACTIVE COMPARATOR

Control group-Total thyroidectomy (TT) with central lymph node dissection (CLND) procedure for patients with papillary thyroid carcinoma (PTC) Standard TT+CLND procedure only

Procedure: Total thyroidectomy (TT)Procedure: Central lymph node dissection (CLND)

Thyroid carcinoma patients (biopsy-proven)-Sentinel lymph node

EXPERIMENTAL

Experimental group- Sentinel lymph node dissection (SLND) after intratumoral indocyanine green (ICG) injection and visualization of all 4 parathyroid glands with infra-red (NIR) fluorescence after intravenous (iv) ICG injection, during total thyroidectomy and central lymph node dissection (CLND). TT+CLND with NIR fluorescence ICG

Procedure: Total thyroidectomy (TT)Procedure: Central lymph node dissection (CLND)Diagnostic Test: Sentinel lymph node (SLN) bopsyDiagnostic Test: Identification of parathyroid glands (PGs)

Interventions

Standard TT procedure for thyroid carcinoma, for both groups

Thyroid carcinoma patients (biopsy-proven)-Sentinel lymph nodeThyroid carcinoma patients (biopsy-proven)-Total thyroidectomy

Standard CLND for thyroid carcinoma, for both groups

Thyroid carcinoma patients (biopsy-proven)-Sentinel lymph nodeThyroid carcinoma patients (biopsy-proven)-Total thyroidectomy

Intrathyroidal injection of ICG for SL biopsy, for only experimental group

Thyroid carcinoma patients (biopsy-proven)-Sentinel lymph node

Near-infrared (NIR) fluorescence visualization of PGs, for only experimental group

Thyroid carcinoma patients (biopsy-proven)-Sentinel lymph node

Eligibility Criteria

Age17 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Thyroid carcinoma patients (biopsy/cytology-proven) suitable for total thyroidectomy procedure
  • Patients at or over 17 years

You may not qualify if:

  • Previous thyroid surgery
  • Patients below 17 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Umraniye Education and Research Hospital, Department of General Surgery

Istanbul, 34760, Turkey (Türkiye)

RECRUITING

Related Publications (2)

  • Zhang X, Shen YP, Li JG, Chen G. Clinical feasibility of imaging with indocyanine green combined with carbon nanoparticles for sentinel lymph node identification in papillary thyroid microcarcinoma. Medicine (Baltimore). 2019 Sep;98(36):e16935. doi: 10.1097/MD.0000000000016935.

  • Spartalis E, Ntokos G, Georgiou K, Zografos G, Tsourouflis G, Dimitroulis D, Nikiteas NI. Intraoperative Indocyanine Green (ICG) Angiography for the Identification of the Parathyroid Glands: Current Evidence and Future Perspectives. In Vivo. 2020 Jan-Feb;34(1):23-32. doi: 10.21873/invivo.11741.

Related Links

MeSH Terms

Conditions

Thyroid NeoplasmsThyroid Cancer, PapillaryLymphatic Metastasis

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsEndocrine System DiseasesThyroid DiseasesAdenocarcinoma, PapillaryAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasm MetastasisNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Ethem Unal, MD, PhD, USMLE&IFSO-CSS, A. Prof.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
A. Prof. of General Surgery and Surgical Oncology

Study Record Dates

First Submitted

June 2, 2020

First Posted

June 11, 2020

Study Start

June 1, 2020

Primary Completion

June 1, 2021

Study Completion

June 1, 2021

Last Updated

June 11, 2020

Record last verified: 2020-06

Data Sharing

IPD Sharing
Will share

Excel data is available upon request at drethemunal@gmail.com

Shared Documents
STUDY PROTOCOL, SAP, CSR
Time Frame
1 year
Access Criteria
Please request study protocol and data (when available) at drethemunal@gmail.com

Locations